RT Journal Article
SR Electronic
T1 Effectiveness of one dose of MVA-BN vaccine against mpox infection in males in Ontario, Canada: A target trial emulation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.04.23296566
DO 10.1101/2023.10.04.23296566
A1 Navarro, Christine
A1 Lau, Cindy
A1 Buchan, Sarah A.
A1 Burchell, Ann N.
A1 Nasreen, Sharifa
A1 Friedman, Lindsay
A1 Okpokoro, Evaezi
A1 Austin, Peter C.
A1 Tan, Darrell HS
A1 Gubbay, Jonathan B.
A1 Kwong, Jeffrey C.
A1 Mishra, Sharmistha
A1 ,
YR 2023
UL http://medrxiv.org/content/early/2023/10/06/2023.10.04.23296566.abstract
AB Background Limited evidence is available on the real-world effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine (MVA-BN) against mpox infection.Methods We emulated a target trial using linked databases in Ontario, Canada to estimate the effectiveness of one dose of MVA-BN. Our study included males aged ≥18 years who: (1) had a history of syphilis testing and a laboratory-confirmed bacterial sexually transmitted infection (STI) in the prior year; or (2) filled a prescription for HIV pre-exposure prophylaxis in the prior year. On each day between June 12, 2022 and October 27, 2022, males who had been vaccinated 15 days prior were matched 1:1 with unvaccinated males by age, geographic region, prior HIV diagnosis, number of bacterial STI diagnoses in the previous three years, and receipt of any non- MVA-BN vaccine in the previous year. We used a Cox proportional hazards model to estimate the hazard ratio comparing the incidence of mpox between the two groups, and calculated vaccine effectiveness as (1–HR)x100.Results Each group included 3,204 males. A total of 71 mpox infections were diagnosed over the study period, with 0.09 (95% confidence interval [CI], 0.05–0.13) per 1000 person-days for the vaccinated group and 0.20 (95%CI, 0.15–0.27) per 1000 person-days for the unvaccinated group. Estimated vaccine effectiveness of one dose of MVA-BN against mpox infection was 59% (95%CI, 31–76%).Conclusions This study, conducted in the context of a targeted vaccination program and evolving outbreak, suggests that one dose of MVA-BN is moderately effective in preventing mpox infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and the Ministry of Long-Term Care. This study also received funding from: the Canadian Immunization Research Network through a grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research (CNF 151944). The Canada-Africa Mpox Partnership, of which this study is one component, was also supported by the Canadian Institutes of Health Research Rapid Mpox Research (MRR-184812). The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. Funders had no role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. JCK is supported by a Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine. SM, DT, and ANB are supported by Tier 2 Canada Research Chairs.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from Public Health Ontario's Ethics Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes